1.62
-0.075(-4.44%)
Currency In USD
| Previous Close | 1.69 |
| Open | 1.71 |
| Day High | 1.71 |
| Day Low | 1.59 |
| 52-Week High | 5.1 |
| 52-Week Low | 0.99 |
| Volume | 200,789 |
| Average Volume | 1.24M |
| Market Cap | 101.89M |
| PE | -1.84 |
| EPS | -0.88 |
| Moving Average 50 Days | 1.5 |
| Moving Average 200 Days | 2.37 |
| Change | -0.08 |
If you invested $1000 in MacroGenics, Inc. (MGNX) 10 years ago, it would be worth $48.76 as of August 06, 2025 at a share price of $1.615. Whereas If you bought $1000 worth of MacroGenics, Inc. (MGNX) shares 5 years ago, it would be worth $58.86 as of August 06, 2025 at a share price of $1.615.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
GlobeNewswire Inc.
Jun 10, 2025 11:00 AM GMT
MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clini
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewswire Inc.
Jun 03, 2025 8:30 PM GMT
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer,
MacroGenics Announces Date of First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 06, 2025 8:30 PM GMT
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, to